In a retrospective study that assessed patients exclusively treated with PSMA PET/CT-guided radiation therapy for recurrent oligometastatic prostate cancer, 59% of oligorecurrences were LN and were treated with an extended irradiation field. This evidence concerns the gene FOLH1 and prostate cancer.